Synapse Open Synapse
Biology

Argenx falls as Sjögren’s setback offsets celiac drug progress

BioPharma Dive · · 3 min read

A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ‘blockbuster expansion opportunity’ for Vyvgart.

Latest from BioPharma Dive